RANI — Rani Therapeutics Holdings Share News
0.000.00%
Last trade - 00:00- $73.40m
- $35.49m
- $1.63m
Rani Therapeutics Q3 net loss widens on higher R&D costs
Rani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Brief: Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Pegbio Co Enters MoU With Rani Therapeutics
Brief: Rani Therapeutics Announces R&D Collaboration With PegBio
Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition
Rani Therapeutics' net loss narrows in Q4 as costs fall
Brief: Rani Therapeutics Announces The Promotion Of Alireza Javadi, Ph.D. To Chief Technical Officer
Rani Therapeutics Q3 net loss decreases, extends cash runway into 2028
Brief: Rani Therapeutics Announces The Appointments Of Abe Bassan And Vasudev Bailey, Ph.D. To Board Of Directors
Brief: Rani Therapeutics Announces Closing Of Oversubscribed $60.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Enter Into A License Agreement For The Development And Commercialization Of An Oral Formulation
U.S. STOCKS ON THE MOVE- SLB NV, Bank OZK, Gilead Sciences
U.S. STOCKS ON THE MOVE- Oklo, Boston Scientific, Agios
Rani Therapeutics more than doubles on over $1 billion licensing deal with Japan's Chugai
U.S. STOCKS ON THE MOVE-Oracle, American Express, Magna International
Rani Therapeutics more than doubles on over $1 billion licensing deal with Japan's Chugai
Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma (updated)
Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma